Cargando…

The role of neoantigen in immune checkpoint blockade therapy

Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing of tumor cell. Due to the interdependence among this series of stepwise events, neoantigen p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Ming, Qin, Shuang, Zhao, Weiheng, Yu, Shengnan, Chu, Qian, Wu, Kongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240277/ https://www.ncbi.nlm.nih.gov/pubmed/30473928 http://dx.doi.org/10.1186/s40164-018-0120-y

Ejemplares similares

Gut microbiome modulates efficacy of immune checkpoint inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

Immune pressures drive the promoter hypermethylation of neoantigen genes
por: Yi, Ming, et al.
Publicado: (2019)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
por: Qin, Shuang, et al.
Publicado: (2019)

Multiple instance learning to predict immune checkpoint blockade efficacy using neoantigen candidates
por: Lang, Franziska, et al.
Publicado: (2023)

Cytosolic Delivery of Thiolated Neoantigen Nano‐Vaccine Combined with Immune Checkpoint Blockade to Boost Anti‐Cancer T Cell Immunity
por: Zhang, Da, et al.
Publicado: (2021)

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
por: Yu, Shengnan, et al.
Publicado: (2017)

Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated anti-tumor immunity
por: Liu, Longchao, et al.
Publicado: (2022)

Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies
por: Li, Shamin, et al.
Publicado: (2021)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
por: Xu-Monette, Zijun Y., et al.
Publicado: (2019)

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
por: Bai, Xianguang, et al.
Publicado: (2019)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
por: D’Alise, Anna Morena, et al.
Publicado: (2019)

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
por: Yi, Ming, et al.
Publicado: (2021)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
por: Xu, Hanxiao, et al.
Publicado: (2018)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Linked CD4(+)/CD8(+) T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
por: Dolina, Joseph S., et al.
Publicado: (2023)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors
por: Wang, Wenwen, et al.
Publicado: (2022)

Neoantigen Tracking: Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer (Adv. Sci. 9/2020)
por: Jia, Qingzhu, et al.
Publicado: (2020)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
por: Anzar, Irantzu, et al.
Publicado: (2023)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis
por: Yi, Ming, et al.
Publicado: (2020)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
por: Yu, Shengnan, et al.
Publicado: (2019)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer
por: Jia, Qingzhu, et al.
Publicado: (2020)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

The Predictive Role of Immune Related Subgroup Classification in Immune Checkpoint Blockade Therapy for Lung Adenocarcinoma
por: Yu, Xiaozhou, et al.
Publicado: (2021)

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8(+) T cells
por: Fehlings, M., et al.
Publicado: (2017)

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
por: Swart, Maarten, et al.
Publicado: (2016)

Immune checkpoint blockade therapy for bladder cancer treatment
por: Kim, Jayoung
Publicado: (2016)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
por: Cremolini, Chiara, et al.
Publicado: (2021)

Metabolic predictors of response to immune checkpoint blockade therapy
por: Shorer, Ofir, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eikc6kb3g2ch05etj4f1i95pas